Answers are grounded in this paper and cite their sources.
Herceptin (trastuzumab) is a human monoclonal antibody that interferes with the HER2 receptor. It is currently the only FDA-approved therapeutic antibody for HER2-positive breast cancer. This article will present the mechanism at action as well as the clinical role at this monoclonal antibody.
No takes yet. Share an insight, caveat, or question.
Gemmete et al. (2011) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: